Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platinum coordination complexes which circumvent cisplatin resistance.

K R Harrap1, L R Kelland, M Jones

  • 1Drug Development Section, Institute of Cancer Research, Sutton, Surrey, U.K.

Advances in Enzyme Regulation
|January 1, 1991
PubMed
Summary

Researchers discovered novel platinum (IV) dicarboxylate compounds for oral administration, showing superior antitumor activity and overcoming resistance in preclinical models. These findings suggest a new generation of platinum-based cancer drugs with broad clinical utility.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

External Beam Radiation Therapy and Immunotherapy in the Management of Hepatobiliary Malignancies: A Meta-analysis of Treatment Response Rates.

International journal of radiation oncology, biology, physics·2026
Same author

Bcl-2 family immunohistochemistry.

Methods in molecular medicine·2011
Same author

Guidelines for the welfare and use of animals in cancer research.

British journal of cancer·2010
Same author

Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents.

Inorganic chemistry·2009
Same author

Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026.

British journal of cancer·2005
Same author

Small molecule anticancer drugs.

IDrugs : the investigational drugs journal·2005

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Pharmacology

Background:

  • Established platinum-based chemotherapy drugs like cisplatin and carboplatin suffer from poor oral bioavailability.
  • Acquired resistance to existing platinum drugs limits their long-term clinical efficacy.
  • There is a need for novel platinum compounds with improved administration routes and broader activity spectra.

Purpose of the Study:

  • To investigate a novel class of platinum (IV) ammine/amine dicarboxylate dichlorides for oral administration.
  • To evaluate the antitumor activity and selectivity of these novel compounds in preclinical cancer models.
  • To assess the efficacy of these compounds against platinum-resistant cancer cell lines and tumors.

Main Methods:

  • Synthesis and characterization of platinum (IV) ammine/amine dicarboxylate dichlorides.

Related Experiment Videos

  • Oral administration of novel platinum compounds to mice bearing ADJ/PC6 plasmacytoma.
  • Evaluation of antitumor activity in human ovarian tumor xenografts and platinum-resistant cell lines (L1210/cisplatin, L1210/tetraplatin).
  • Establishment of in vitro and in vivo human ovarian carcinoma models to predict clinical response.

    • Main Results:

    • Novel platinum (IV) dicarboxylates demonstrated superior antitumor selectivity compared to intraperitoneal cisplatin or carboplatin in mice.
    • Comparable oral activity to intraperitoneal cisplatin and carboplatin was observed in human ovarian tumor xenografts.
    • These platinum (IV) compounds retained cytotoxicity against acquired cisplatin- and tetraplatin-resistant cell lines.
    • Efficacy against platinum-resistant ADJ/PC6 tumors varied, highlighting the complexity of resistance mechanisms.

    Conclusions:

    • Platinum (IV) ammine/amine dicarboxylates show significant promise as orally administered therapeutic agents.
    • These novel compounds may overcome resistance mechanisms associated with existing platinum drugs.
    • The developed human ovarian carcinoma models may serve as predictive tools for platinum-based therapy, supporting the development of a new generation of platinum drugs.